Psammaplin A
97%
- Product Code: 110105
CAS:
110659-91-1
| Molecular Weight: | 664.39 g./mol | Molecular Formula: | C₂₂H₂₄Br₂N₄O₆S₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C, dry, sealed |
Product Description:
Psammaplin A is primarily recognized for its potential in cancer research due to its ability to inhibit histone deacetylase (HDAC) and DNA methyltransferase (DNMT). These inhibitory properties make it a promising candidate for epigenetic therapy, which aims to reverse abnormal gene expression patterns in cancer cells. By targeting these enzymes, Psammaplin A can potentially reactivate tumor suppressor genes and inhibit cancer cell proliferation. Additionally, its dual inhibitory action on both HDAC and DNMT sets it apart from other compounds, offering a unique approach to epigenetic modulation. Beyond oncology, Psammaplin A has shown antimicrobial activity, particularly against certain bacterial and fungal strains, suggesting its utility in developing new antimicrobial agents. Research is also exploring its anti-inflammatory and antioxidant properties, which could be beneficial in treating chronic inflammatory diseases and reducing oxidative stress-related damage. Overall, Psammaplin A holds significant promise in multiple therapeutic areas, particularly in cancer treatment and antimicrobial development.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Light Yellow Solid |
| Purity (%) | 96.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | €222.14 |
+
-
|
| 0.005 | 10-20 days | €736.06 |
+
-
|
Psammaplin A
Psammaplin A is primarily recognized for its potential in cancer research due to its ability to inhibit histone deacetylase (HDAC) and DNA methyltransferase (DNMT). These inhibitory properties make it a promising candidate for epigenetic therapy, which aims to reverse abnormal gene expression patterns in cancer cells. By targeting these enzymes, Psammaplin A can potentially reactivate tumor suppressor genes and inhibit cancer cell proliferation. Additionally, its dual inhibitory action on both HDAC and DNMT sets it apart from other compounds, offering a unique approach to epigenetic modulation. Beyond oncology, Psammaplin A has shown antimicrobial activity, particularly against certain bacterial and fungal strains, suggesting its utility in developing new antimicrobial agents. Research is also exploring its anti-inflammatory and antioxidant properties, which could be beneficial in treating chronic inflammatory diseases and reducing oxidative stress-related damage. Overall, Psammaplin A holds significant promise in multiple therapeutic areas, particularly in cancer treatment and antimicrobial development.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
€0.00
€0.00
Total :